Rare or dysfunctional variants may impair AAT function despite ‘intermediate’ serum concentrations, while clinical modifiers—exacerbation burden, HRCT emphysema pattern/airway involvement, bronchiectasis/asthma overlap, and smoking history—can amplify neutrophil-driven inflammation beyond antiprotease capacity. This evidence concerns the gene SERPINA1 and pulmonary emphysema.